Denali Therapeutics - About the company
Denali Therapeutics is a public company based in San Francisco (United States), founded in 2015 by Marc Tessier Lavigne, Ryan Watts and Alexander Schuth. It operates as a Developer of therapies to treat neurodegenerative diseases. Denali Therapeutics has raised $347M in funding. The company has 465 active competitors, including 166 funded and 87 that have exited. Its top competitors include companies like Fulcrum Therapeutics, Evommune and Annexon.
Sectors and market segments that Denali Therapeutics operate in
Denali Therapeutics serves in the Life Sciences market segments.The primary business model of Denali Therapeutics are:Company Details
Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.
- Website
- www.denalitherapeutics.com/
- Registered Address
- South San Francisco, California
Key Metrics
Founded Year
2015
Location
San Francisco, United States
Stage
Public
Total Funding
$347M in 3 rounds
Latest Funding Round
Investors
Ranked
1st among 465 active competitors
Annual Revenue
$331M as on Dec 31, 2023
Employee Count
576 as on May 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Denali Therapeutics
Denali Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Denali Therapeutics Inc. CIN: 1714899 , United States, Active | Oct 13, 2013 | $331M (As on Dec 31, 2023) | - | - |
DENALI THERAPEUTICS, INC. CIN: 463872213 , United States, Active | Dec 31, 1999 | - | 410 (As on Dec 31, 2024) | - |
Denali Therapeutics's IPO details
Denali Therapeutics got listed on Dec 08, 2017.
Click here to take a look at Denali Therapeutics's IPO in detail
Sign up to download Denali Therapeutics' company profile
Denali Therapeutics's funding and investors
Denali Therapeutics has raised a total funding of $347M over 3 rounds. Its first funding round was on May 14, 2015. Denali Therapeutics has 12 institutional investors.
Here is the list of recent funding rounds of Denali Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 27, 2024 | $500M | Post IPO | - | - | - | - |
Aug 25, 2016 | $130M | Series B | - | - | - | |
May 14, 2015 | $217M | Series A | - | - | - |
Access funding benchmarks and valuations. Sign up today!View details of Denali Therapeutics's funding rounds and investors
Denali Therapeutics' founders and board of directors
Founder? Claim ProfileHere are the details of Denali Therapeutics' key team members:
- Marc Tessier Lavigne: Former Co-Founder of Denali Therapeutics. Contact Info: 1 email address
- Ryan Watts: Co-Founder & CEO of Denali Therapeutics. Contact Info: 1 email address
- Alexander Schuth: Co-Founder, Chief Operating and Financial Officer of Denali Therapeutics. Contact Info: 2 email addresses
View details of Denali Therapeutics's Founder profiles and Board Members
Denali Therapeutics' employee count trend
Denali Therapeutics has 576 employees as of May 26. Here is Denali Therapeutics's employee count trend over the years:
Uncover Denali Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Denali Therapeutics's Competitors and alternates
Top competitors of Denali Therapeutics include Fulcrum Therapeutics, Evommune and Annexon. Here is the list of Top 10 competitors of Denali Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 72/100 | |
2nd |  Fulcrum Therapeutics 2015, Cambridge (United States), Public | Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 71/100 | |
3rd |  Evommune 2020, Sacramento (United States), Public | Developer of therapeutic options for chronic inflammatory disorders | $276M | 69/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th |  Ventyx Biosciences 2018, Encinitas (United States), Acquired | Developer of therapeutics to treat autoimmune diseases | $165M | 66/100 | |
6th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 65/100 | |
7th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
8th |  Sonoma Biotherapeutics 2012, San Francisco (United States), Series B | Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 64/100 | |
9th | Alchemab 2019, London (United Kingdom), Series A | Developer of antibody therapeutics for treating oncology and neurodegenerative conditions | $115M | 64/100 | |
10th | US World Meds 2001, Louisville (United States), Series B | Developer of therapeutics for the treatment of multiple diseases | $149M | 63/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Denali Therapeutics's competitors? Click here to see the top ones
Denali Therapeutics's Investments and acquisitions
Denali Therapeutics has acquired Triller. Denali Therapeutics has not made any investments as of now.News related to Denali Therapeutics
Filter this listMedia has covered Denali Therapeutics for a total of 21 events in the last 1 year, 13 of them have been about company updates and 1 about partnerships.
•
•
•
FDA Clears Denali's 'Game-Changer' Hunter Syndrome Drugpharmaphorum•Mar 26, 2026•Denali Therapeutics, Takeda
•
AlphaQuest LLC Raises Stake in Denali Therapeutics Inc. $DNLIMarketBeat•Feb 02, 2026•AlphaQuest, Denali Therapeutics
•
•
•
•
•
Edgestream Partners L.P. Acquires 59,253 Shares of Masco Corporation $MASMarketBeat•Dec 02, 2025•EdgeStream LP, Masco Corporation, Citi, O'Reilly Auto Parts and 5 others
•
Schroder Investment Management Group Purchases 394,148 Shares of PDD Holdings Inc. Sponsored ADR $PDDMarketBeat•Nov 30, 2025•PDD Holdings, Schroders, O'Reilly Auto Parts, Tapestry and 23 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Denali Therapeutics
Explore our recently published companies
- Inadev - Reston based, 2011 founded, Unfunded company
- Empirical Investments Resource Management - Barueri based, 2009 founded, Unfunded company
- Ncyrmy.com.cn - China based, 2022 founded, Unfunded company
- Vector Airconditioning - Gurugram based, Unfunded company
- Sunrise Engineering - Navi Mumbai based, 2002 founded, Unfunded company
- Ace Finepack - Ernakulam based, 1988 founded, Unfunded company
